Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Plain-language summary

This study examined how Disulfiram, a medication used to treat alcohol dependence, affects the processing of amyloid precursor protein, which is linked to Alzheimer's disease. It included outpatients and inpatients receiving Disulfiram for relapse prevention. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Johannes Gutenberg University Mainz

Intervention

Disulfiram

Start date

5/1/2013

Estimated completion

7/1/2017

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

ambulant or stationary patients, which receive Disulfiram for recrudescence prevention

Exclusion Criteria:

Diagnosed Alzheimer's dementia Previous Disulfiram treatment less than four weeks before baseline blood collection